| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000037738 |
| Receipt No. | R000043035 |
| Scientific Title | Efficacy trial of single intake of plant derived ingredient. [g2019004] |
| Date of disclosure of the study information | 2019/08/20 |
| Last modified on | 2022/04/13 (Ver. 4) |
| Basic information | ||
| Public title | Efficacy trial of single intake of plant derived ingredient. [g2019004] | |
| Acronym | Efficacy of plant derived ingredient [g2019004] | |
| Scientific Title | Efficacy trial of single intake of plant derived ingredient. [g2019004] | |
| Scientific Title:Acronym | Efficacy of plant derived ingredient [g2019004] | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate effects of a plant derived ingredient on gastrointestinal hormone in healthy male adults |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Postprandial GLP-1 concentration (baseline, 30, 60, 90, 105, and 120 minutes after ingestion of a test meal) |
| Key secondary outcomes | Postprandial concentration of glucose, insulin and GIP (baseline, 30, 60, 90, 105, and 120 minutes after ingestion of a test meal) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 6 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Single consumption of control food > wash out (1 week) > Single consumption of test food A consumption > wash out (1 week) > Single consumption of test food B consumption | |
| Interventions/Control_2 | Single consumption of control food > wash out (1 week) > Single consumption of test food B consumption > wash out (1 week) > Single consumption of test food A consumption | |
| Interventions/Control_3 | Single consumption of test food A consumption > wash out (1 week) > Single consumption of test food B consumption > wash out (1 week) > Single consumption of Control food consumption | |
| Interventions/Control_4 | Single consumption of test food A consumption > wash out (1 week) > Single consumption of Control food consumption > wash out (1 week) > Single consumption of test food B consumption | |
| Interventions/Control_5 | Single consumption of test food B consumption > wash out (1 week) > Single consumption of test food A consumption > wash out (1 week) > Single consumption of Control food consumption | |
| Interventions/Control_6 | Single consumption of test food B consumption > wash out (1 week) > Single consumption of Control food consumption > wash out (1 week) > Single consumption of test food A consumption | |
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | (1) Adult aged from 30 y to 65 y
(2) Fasting glucose from 95 to 125 mg/dL |
|||
| Key exclusion criteria | (1) Diabetes mellitus
(2) Taking medicine related diabetes mellitus (3) BMI<=30kg/m2 (4) Having history or presence of cardiovascular disease or cerebrovascular disease (5) Presence of liver, kidney or respiratory disease, endocrine disorder, metabolic disorder, organ disorder, gout, rheumatism, autoimmune disease, allergy disease, mental disorder, cancer, infection disease, or other diseases (6) Having history of resection of gastrointestinal tract (7) Thyroid deficiency (8) Heavy alcohol drinker (over 30g per day) (9) Donated over 200 mL of blood within the last one month prior to the study or over 400 mL of blood within the last three months prior to the study (10) Severe anemia (Hb <=7g/dL) (11) Food allergies for test foods (12) Planned to participate in other clinical study during current study (13) Shift worker (14) Determined to be unqualified by the physician in charge or the responsible person of the study |
|||
| Target sample size | 18 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Biological Science Research laboratories | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, Japan | ||||||
| TEL | 03-5630-7456 | ||||||
| saito.shinichiro@kao.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Biological Science Research laboratories | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, Japan | ||||||
| TEL | 03-5630-7476 | ||||||
| Homepage URL | |||||||
| yanagimoto.aya@kao.com | |||||||
| Sponsor | |
| Institute | Kao Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Ueno-Asagao Clinic Ethical Review Committee |
| Address | Kairaku Building 6F, 2-7-5, Higashiueno, Taito-ku, Tokyo, 110-0015, Japan |
| Tel | 03-6240-1162 |
| jimukyoku@tes-h.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Unpublished due to the protocol including the intellectual property rights |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | works in progress | ||||||
| Number of participants that the trial has enrolled | 18 | ||||||
| Results | A significant difference was observed in the primary outcome. | ||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Healthy adults | ||||||
| Participant flow | 16 participants completed and 18 subjects were incorporated into the analyses (2 participant declined due to personal reasons) | ||||||
| Adverse events | none | ||||||
| Outcome measures | gastrointestinal hormone | ||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043035 |